Printer Friendly
The Free Library
19,595,263 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

AmBisome gains marketing approval in India.


BOULDER, Colo.--(BUSINESS WIRE)--May 13, 1996--NeXstar Pharmaceuticals, Inc. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
:NXTR) announced today that the Indian Ministry of Health has granted an import license and final marketing approval for AmBisome, the Company's liposomal formulation of amphotericin B amphotericin B (ăm'fətĕr`ĭsĭn), antibiotic that halts the growth of several disease-causing fungi. Discovered in 1956, it is produced by bacteria of the genus Streptomyces. .

AmBisome is indicated for the treatment of life-threatening systemic fungal infections Fungal infections

Several thousand species of fungi have been described, but fewer than 100 are routinely associated with invasive diseases of humans.
 that fail to respond to amphotericin B therapy. India is the 24th country to approve AmBisome. Two countries, Ireland and Australia, have approved AmBisome for use as a primary therapy for the treatment of confirmed or suspected fungal infections.

AmBisome has completed clinical trials in over 1000 patients in Europe and is completing phase III clinical trials in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . The Company expects to complete its new drug application in the U.S. shortly.

NeXstar Pharmaceuticals, Inc. is an integrated pharmaceutical company engaged in the discovery, development, manufacturing and marketing of products to treat life-threatening diseases. The Company currently markets two drugs, AmBisome and DaunoXome. The Company has headquarters in Boulder, Colorado; research, development and manufacturing facilities in San Dimas, California San Dimas is a city located in Los Angeles County, California. As of the 2004 census, the city had a total population of 36,200. History
Don Palomares received a 15,000 acre (61 km) 
; Antwerp, Belgium; Lakewood, Colorado, and Boulder; and marketing subsidiaries worldwide.

CONTACT: NeXstar Pharmaceuticals,

Joseph Alper, (303) 546-7717
COPYRIGHT 1996 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:May 13, 1996
Words:187
Previous Article:Del Webb among top three fastest-growing builders; developer of Sun Cities honored by Builder magazine.
Next Article:Mobil begins engineering for Saudi Petrochemicals complex expansion.
Topics:



Related Articles
Fujisawa, NeXstar to co-promote AmBisome in the United States.
NEW DATA DEMONSTRATES AMBISOME COST EFFECTIVENESS.
NeXstar Pharmaceuticals, Sumitomo Pharmaceuticals Sign License and Distribution Agreement for AmBisome in Japan.
FDA Antiviral Drug Committee Finds AmBisome Safe and Effective for Treatment of FUO.
IN-STATE CALLER I.D. TO START SATURDAY FOR PACIFIC BELL, GTE.
Dainippon Sumitomo Pharma Receives Approval for Antifungal Agent AmBisome.
Dainippon Sumitomo Pharma to Release AmBisome 50mg, Antifungal Agent for Deep-seated Mycosis Infection.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles